Cook Medical Enrolls First U.S. Patient in STABLE Aortic Dissection Trial

Leading Vascular Surgeons Treat First U.S. Patient in Groundbreaking Trial at Thomas Jefferson University Hospital
BLOOMINGTON, Ind.--(BUSINESS WIRE)--Cook Medical today announced enrollment of the first U.S. patient in the STABLE global clinical trial designed to evaluate the Cook Zenith® Dissection Endovascular System for the treatment of Type B thoracic aortic dissections. This is the first device designed specifically to treat aortic dissections, the condition that took the life of actor John Ritter. The technologically advanced device is the first-of-its-kind worldwide and was designed to treat the unique morphology of this disease, a major cause of mortality worldwide.

press release >> http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20080211005332&newsLang=en